Project Grant R01DA065307
- The National Institute on Drug Abuse awarded the University of Washington $100,228 on November 10, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to characterize the role of endogenous nociceptin opioid release from the central amygdala in reward outcome encoding. The recipient will conduct research examining how nociceptin-containing neurons in the central amygdala engage distinct reward properties—including reward probability and size—and project to the lateral...
- The National Institute on Drug Abuse awarded the University of Washington $2,121,054 through the Drug Use and Addiction Research Programs (CFDA 93.279) on September 15, 2025, for a five-year project grant to optimize opioid use disorder treatment strategies in prisons. The research validates two practical, scalable tools for identifying opioid use disorder (OUD) in correctional settings and engaging incarcerated individuals in medication for opioid use disorder (MOUD) treatment. The first tool...
- The National Institute on Drug Abuse awarded the University of Washington $672,701 on February 15, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to implement HIV screening and prevention in low-barrier office-based opioid treatment programs. The research will improve the HIV screening and treatment cascade among patients receiving medications for opioid use disorder at four primary care-integrated opioid treatment programs at Harborview Medical Center in Seattle. The...
- The National Institute on Drug Abuse awarded the University of Washington $139,812 on August 6, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to conduct basic research on serotonin and dopamine dynamics during kappa opioid-mediated aversion. This Project Grant (F31DA065365) funds investigation of how stress-induced activation of the dynorphin-kappa opioid receptor system modulates serotonin and dopamine signaling in the brain, with implications for understanding...
- The National Institute on Drug Abuse awarded the University of Washington $668,939 on June 1, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to conduct a hybrid type I effectiveness-implementation study testing the MIAPP (mHealth Incentivized Adherence Plus Patient Navigation) intervention for improving treatment linkage and medication adherence in patients initiated on buprenorphine in the hospital. The intervention combines financial incentives for medication...
- The National Institute on Drug Abuse awarded Washington State University $604,683 on August 1, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to dissect the role of thalamic withdrawal-encoding ensembles in opioid use disorder through basic neuroscience research. The recipient will employ viral trap technology and multilevel circuit-based approaches—including ex vivo electrophysiology, optogenetics, in vivo calcium imaging, and fiber photometry—to characterize the...
- Federal Grant Award Summary The University of Washington received a $4.665 million Project Grant award from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) effective June 15, 2025, through May 31, 2029. This grant supports the development and testing of the Community-Based Opioid Treatment (CBOT) implementation strategy, a nurse-led care delivery model designed to provide buprenorphine and HIV prevention and care services to people who...
- The National Institute on Drug Abuse (NIDA) awarded a Cooperative Agreement of $733,457 to The Washington University on May 1, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279). The award funds research investigating the long-term neurodevelopmental impact of maternal opioid exposure and opioid management strategies in rodent offspring. The project evaluates how in utero oxycodone exposure, maintenance therapy with methadone and buprenorphine, and withdrawal mitigation...
- The National Institute on Drug Abuse awarded Seattle Children's Hospital (doing business as Seattle Children's Research Institute) $574,954 in funding for Project Grant R01DA061865 on May 1, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279). The project investigates homeostatic mechanisms of the brain's locus coeruleus noradrenergic system in opioid use disorder as a contributor to opioid-induced sleep disturbances. Sleep dysfunction in opioid use disorder drives...
- The National Institute on Drug Abuse awarded The Washington University $1,155,062 on March 15, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to generate multiomics data characterizing cellular mechanisms underlying fentanyl-induced respiratory depression in opioid overdose decedents. The award funds single-nucleus RNA-seq and ATAC-seq (snRNAseq and snATACseq) paired multiomics analysis of brainstem respiratory control regions—the prebotzinger complex and ventral...
The National Institute on Drug Abuse awarded the University of Washington $1,469,150 on August 15, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to conduct research on the impact of recurring severe weather events on fatal and non-fatal opioid overdose. The research integrates high spatiotemporal resolution datasets on severe weather—temperature, tropical cyclone, wildfire fine particulate matter, and wildfire disasters—with nationwide health datasets to examine the extent to which heatwaves, tropical cyclones, and wildfires increase opioid overdose risk. The project investigates how severe weather may affect people who use drugs through physiological impacts, stress, displacement and homelessness, reduced access to healthcare and harm reduction services, and interruption of opioid use disorder treatment. The work seeks to identify who is most affected—including examination of individual and community-level factors such as rurality, treatment access, and medication for opioid use disorder type—and to delineate mediating pathways that could support targeted policy interventions. The University of Washington's Office of Sponsored Programs, administering the award through its Grant & Contracts Division, serves as the prime recipient. Performance occurs in Seattle, Washington, with a period of performance extending through May 31, 2031. This is a Project Grant assistance type supporting basic, clinical, translational, and implementation research in substance use as defined by the CFDA program.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $0 | 8/31/26 | ||
| Not listed | $734.6k | 8/7/26 |